Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/02/2025 10:30 PDT] Evelo Biosciences, Inc. (NASDAQ:EVLO), Up By 0% ($0) From $0 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/27/2025 07:25 PDT] EVLO Expected to Trade Up After Bullish Patterns Develop
• [05/23/2025 07:49 PDT] EVLO Expected to Trade Up After Bullish Patterns Develop
• [05/22/2025 07:25 PDT] EVLO Expected to Trade Up After Bullish Patterns Develop